Effect of febuxostat on cardiac function in elderly patients with chronic heart failure accompanied by hyperuricemia

Abstract

Objective To observe the effect of febuxostat on cardiac function in elderly patients with chronic heart failure(CHF)complicated with hyperuricemia. Methods Total 150 elderly CHF patients with HUA in the First People's Hospital of Jining were selected from October 2016 to August 2017, randomly divided into two groups: routine treatment group(control group)and febuxostat group(treatment group), 75 cases in each group.Two groups were standardized according to the 2016 European Heart Association guidelines for heart failure treatment, the treatment group was additionally treated with febuxostat 40 or 80 mg/d for 6 months.The left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD)were measured by echocardiography before and after treatment, the left ventricular ejection fraction(LVEF)was calculated, serum uric acid and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels, 6 min walk distance(6MWD)were measured simultaneously. Results (1)After treatment for 6 months, the serum uric acid level in the treatment group was significantly lower than that in the control group [(325.36±37.57)μmol/L vs.(421.14±50.21)μmol/L, t=4.236 2, P=0.001 2]. (2)After treatment for 6 months, the serum uric acid, NT-proBNP, LVESD and LVEDD of the patients were decreased in the treatment group and the control group, and the decrease in the treatment group was more obvious(P<0.05). While LVEF and 6MWD showed an upward trend, the treatment group was more significant than the control group, with a significant difference(P<0.05). Conclusions Febuxostat can decrease the serum level of uric acid in elderly CHF patients with HUA, and significantly improve their cardiac function. Key words: Febuxostat; Hyperuricemia; Heart failure; Aged; Cardiac function